ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

elifibranor

Also written as “Elafibranor”, “GFT505 80mg” and “elafibranor”.

Its studies are mostly in Liver Cirrhosis, Biliary · Non-alcoholic Fatty Liver Disease · Cholangitis, Sclerosing · Diabetes Mellitus, Type 2 · Renal Insufficiency, led by 2 companies.

Drug pageElifibranor: every studyAll 23 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Feb 16, 201624 company-led studies, 5 open or runningNext primary completion: Dec 17, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Genfitits history only160 open or runningphase 3since Feb 16, 2016Dec 13, 2010none ahead
Ipsen85 open or runningphase 3since Aug 21, 2020Aug 21, 2020Dec 17, 2026phase 3 · NCT06730061

Also a collaborator on its studies: Naturalpha, Premier Research Group, Eurofins Optimed and PhinC Development.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Ipsen only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 21, 2020First study: phase 3 study in Liver Cirrhosis, BiliaryFirst studyNCT04526665 · 161 enrolled · United States, Argentina, Belgium and more
  2. Sep 14, 20222 phase 1 studiesNCT05543369, NCT05564208
  3. Nov 22, 2022Phase 2 study in Cholangitis, SclerosingNCT05627362 · 68 enrolled · United States, Canada, Germany and more
  4. Aug 22, 2023Phase 3 study in Liver Cirrhosis, BiliaryNCT06016842 · 276 planned · United States, Argentina, Australia and more
  5. Apr 22, 2024Phase 3 study in Liver Cirrhosis, BiliaryNCT06383403 · 92 enrolled · United States, Czechia, France and more
  6. Dec 3, 2024Phase 3 study in Liver Cirrhosis, BiliaryNCT06730061 · 18 enrolled · Japan
  7. Jan 28, 2026Phase 3 study in Cholangitis, SclerosingNCT07387549 · 350 planned · United States, Argentina, Australia and more

Ahead

  1. Dec 17, 2026Primary completion: phase 3 study in Liver Cirrhosis, BiliaryNCT06730061
  2. May 31, 2029Primary completion: phase 3 study in Liver Cirrhosis, BiliaryNCT06016842
  3. Apr 30, 2031Primary completion: phase 3 study in Cholangitis, SclerosingNCT07387549
  4. Sep 23, 2031Primary completion: phase 2 study in Cholangitis, SclerosingNCT05627362

TargetBeta

PPARA →read by rule
“An orally bioavailable agonist of peroxisome proliferator-activated receptor (PPAR)-alpha (PPARa) and -delta (PPARd), with bile acids reducing activity”NCIt, by rule

Other programs on PPARA

ProgramCompanyFurthest phaseStudies
saroglitazarruleZydus Lifesciencesphase 419
pemafibrateruleKowaphase 417
seladelparruleGilead Sciencesphase 314
chiglitazarruleChipscreen Biosciencesphase 39
Gemfibrozilrulepolaryx-therapeutics-incphase 38
lanifibranorinventiva-pharmaphase 36

Studies

All 8 Ipsen leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07387549Cholangitis, Sclerosing · United States, Argentina, Australia and more3RecruitingApr 30, 2031350
NCT06730061Liver Cirrhosis, Biliary · Japan3Active, not recruitingDec 17, 202618
NCT06383403Liver Cirrhosis, Biliary · United States, Czechia, France and more3CompletedJun 16, 202692
NCT06016842Liver Cirrhosis, Biliary · United States, Argentina, Australia and more3RecruitingMay 31, 2029276
NCT05627362Cholangitis, Sclerosing · United States, Canada, Germany and more2Active, not recruitingSep 23, 203168
NCT05564208Healthy Participants · France1CompletedDec 30, 202234
NCT05543369Healthy Volunteers · United States1CompletedMar 10, 202348
NCT04526665Liver Cirrhosis, Biliary · United States, Argentina, Belgium and more3Active, not recruitingJun 1, 2023161

How it is read

Names in the registry

  • “Elafibranor”, 8 entries
  • “GFT505 80mg”, 5 entries
  • “elafibranor”, 4 entries
  • “Elafibranor 80mg”, 2 entries
  • “Elafibranor 80 mg”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.